How Does ECT Work for Catatonia?

Electroconvulsive therapy is one of the most effective treatments available for catatonia, with response rates between 80% and 100% reported across the literature. That makes it arguably the most successful intervention in all of psychiatry for any single condition. ECT is typically reserved for cases where benzodiazepines, the standard first-line treatment, have not worked, but in life-threatening forms of catatonia it may be used much earlier. The story of how and when ECT gets deployed for catatonia, and why access remains uneven despite the strong evidence, is more complicated than those headline numbers suggest.

What Catatonia Actually Looks Like

Catatonia is not a disease in its own right but a syndrome, a recognizable cluster of motor and behavioral signs that can show up across a range of psychiatric and medical conditions. More than 40 distinct signs have been catalogued, but clinicians generally look for at least two prominent features lasting 24 hours or longer. Those features can include immobility, mutism, staring, posturing (holding an unusual position for a long time), waxy flexibility (where someone’s limb stays wherever you move it), agitation, repetitive movements, or refusal to eat or drink.

Roughly one in ten acutely ill psychiatric inpatients meets criteria for catatonia, and mood disorders are actually a more common trigger than schizophrenia, which surprises many people familiar only with older textbook descriptions.¹ Catatonia also shows up in medical conditions like autoimmune encephalitis, metabolic disturbances, and drug reactions. It presents mainly in two forms: a retarded-stuporous type, where the person is largely immobile and unresponsive, and an excited-delirious type, where agitation and purposeless movement dominate. The retarded form is more commonly recognized, but the excited form can be just as dangerous.

At its worst, catatonia can become “malignant,” marked by fever, autonomic instability (wild swings in heart rate, blood pressure, and temperature), and breakdown of muscle tissue. Malignant catatonia is a medical emergency with a real risk of death if untreated.² This is often where ECT becomes not just helpful but urgent.

Why Benzodiazepines Come First

The standard treatment algorithm starts with benzodiazepines, most commonly lorazepam given intravenously or orally. The idea is straightforward: catatonia involves a reduction in the brain’s inhibitory signaling, particularly through the neurotransmitter GABA, and benzodiazepines boost GABA activity.³ In a classic early treatment study, 28 catatonic patients were treated with lorazepam for up to five days, with ECT reserved for those who did not respond. Four patients who failed lorazepam responded promptly to ECT.⁴

Many patients do respond to benzodiazepines alone, especially when the catatonia is caught early and the underlying condition is addressed. But a substantial minority does not, and that is where ECT enters the picture. The clinical consensus, supported by treatment reviews, is that ECT should be used when benzodiazepines fail or when catatonia is malignant and time is critical.⁵

How Effective ECT Is for Catatonia

The numbers here are striking by psychiatric standards. A systematic review of the literature found that ECT is effective across all forms of catatonia, including cases where benzodiazepines have already failed, with response rates ranging from 80% to 100%. The authors described these results as superior to those of any other therapy in psychiatry.⁶ A separate study examining ECT for catatonia across different age groups confirmed these high response rates and described ECT as safe and highly effective across the lifespan.⁷

To put this in context, most psychiatric treatments work well for some people and not at all for others. Response rates of 50% to 60% are considered respectable for antidepressants, for instance. An intervention that reliably produces improvement in four out of five patients, and often closer to all of them, occupies a different category entirely. The evidence is not from large randomized controlled trials, which are difficult to run in catatonia for both practical and ethical reasons, but it is consistent and compelling across case series and systematic reviews.

What Happens During ECT for Catatonia

ECT involves delivering a carefully controlled electrical current to the brain while the patient is under general anesthesia, with a muscle relaxant to prevent injury during the induced seizure. The whole procedure typically takes a few minutes, and the patient wakes up shortly afterward. For catatonia, sessions are usually given every other day, with a course running from about 8 to 12 sessions depending on how the patient responds.

Electrode placement is one area where clinical practice is evolving. Historically, bilateral (bitemporal) electrode placement was the default for catatonia. But a case series using right unilateral placement in five benzodiazepine-resistant catatonic patients found that four of the five fully recovered, and the fifth achieved partial response. All patients tolerated the treatments without major side effects.⁸ A more recent naturalistic case series found that 90% of catatonic patients responded to right unilateral placement and 70% achieved full remission. Patients with delirious mania and neuroleptic malignant syndrome all remitted with ultrabrief pulse right unilateral ECT, and cognition remained stable or improved throughout treatment.⁹

Right unilateral placement matters because it tends to produce fewer cognitive side effects than bilateral placement, particularly less post-treatment confusion and memory disruption. If it works equally well for catatonia, and the early data suggests it often does, it becomes the preferred approach for many clinicians. The ultrabrief pulse width used in the more recent study further reduces the charge delivered to the brain, which is associated with even less cognitive impact.

Side Effects and Safety

The side effects reported in ECT for catatonia are broadly the same as those seen with ECT for depression: temporary mental confusion around the time of treatment, headache, and memory difficulties. A systematic review and meta-analysis of ECT for catatonia found that when adverse effects were reported at all, they consisted of mental confusion, memory loss, headache, or effects related to anesthesia.¹⁰ These are generally short-lived, and the cognitive profile described in more recent studies using right unilateral placement has been reassuring, with cognition remaining stable or improving over the treatment course.¹¹

There is an important asymmetry to weigh when thinking about risks. Untreated catatonia, especially the malignant form, can cause kidney failure, blood clots, aspiration pneumonia, and death. A treatment with temporary confusion and headache as its main downsides looks very different when the alternative is a potentially fatal syndrome that is not responding to medication.

Catatonia in Children, Adolescents, and Autistic Individuals

One of the more contentious areas is the use of ECT in young people. In many countries, ECT in minors carries extra legal scrutiny and social stigma. But the clinical evidence supports its use for catatonia in this age group. A review of 59 reported cases found ECT to be safe and effective in children and adolescents with catatonia.¹² A systematic review of the broader pediatric ECT literature concluded that ECT should be considered for severe, treatment-resistant conditions including catatonia, particularly in older adolescents.¹³

Catatonia occurs disproportionately in people with autism spectrum conditions, and this population presents unique challenges. Autistic individuals with catatonia often develop severe self-injurious behavior that resists conventional treatment. A study examining ECT outcomes in autistic versus non-autistic catatonic patients found clinical improvement in both groups: all autistic patients and about 89% of non-autistic patients showed a clinical response. Among autistic patients, self-injury prevalence dropped from roughly 43% to 17%, and aggression improved in both groups. Documented adverse events were uncommon.¹⁴

What sets this population apart is the duration and intensity of treatment that may be required. In a study of catatonia treatment in autistic patients, nearly all had failed initial benzodiazepine trials and went on to ECT, starting at a mean age of about 15 and a half years. The total number of ECT sessions ranged enormously, from 16 to 688, and most patients were still receiving maintenance ECT when the study period ended. Despite the heavy treatment burden, ECT conferred substantial benefit, including relief from incapacitating self-injury that had not responded to any other intervention.¹⁵ Clinicians familiar with these cases often describe ECT as the only treatment that kept certain patients alive and functional.¹⁶

Preventing Relapse With Maintenance ECT

Catatonia has a frustrating tendency to recur. After a successful acute course of ECT, some patients relapse when sessions stop, sometimes within days or weeks. This is where maintenance ECT becomes relevant: periodic sessions, often given weekly or biweekly at first and gradually spaced out, to prevent symptoms from returning.

Maintenance ECT has been described as a safe and well-tolerated strategy for preventing relapses in severe catatonic patients who have previously stabilized with acute ECT.¹⁷ In relapse-prone patients, particularly middle-aged and older adults with catatonic schizophrenia, adjusting the frequency of maintenance sessions to be more frequent has been shown to successfully prevent recurrence.¹⁸

The trade-off is obvious: maintenance ECT means repeated anesthesia exposures and ongoing disruption to daily life. For patients whose catatonia keeps returning and who have no other effective option, the calculus typically favors continuing. For the autistic patients described above, some of whom had received hundreds of sessions, the treatment essentially becomes a long-term management strategy rather than a cure. This is not ideal, but the alternative for many of these patients was uncontrolled self-harm or complete loss of function.

Catatonia From Autoimmune Encephalitis

A growing area of interest is catatonia caused not by psychiatric conditions but by autoimmune brain inflammation, particularly anti-NMDA receptor encephalitis. This condition, in which the body’s immune system attacks a specific type of brain receptor, often presents with psychiatric symptoms including severe catatonia, especially in young women. The standard treatment is immunotherapy: steroids, plasma exchange, or intravenous immunoglobulins. But when the psychiatric symptoms do not clear despite immunological treatment, ECT has shown promise.

A systematic review of 30 cases found that most patients were young women with catatonia. Symptoms improved in about 65% of cases, and interestingly, some of those improvements occurred even without immunomodulatory therapy being given at the same time. ECT proceeded without complications in roughly 87% of cases.¹⁹ A separate systematic review of 26 patients with autoimmune encephalitis treated with ECT found a favorable response in more than three-quarters of cases, with serious side effects reported in only 3 of the 26 patients.²⁰

Case reports further illustrate the pattern. One described a 71-year-old woman who initially presented with depression that escalated to catatonia and psychosis. After anti-NMDA receptor antibodies were discovered, she received plasma exchange and steroids with only partial improvement. Multiple ECT sessions resolved her psychiatric symptoms completely and she returned to her baseline level of functioning.²¹ These cases are pushing clinicians to think of ECT not just as a psychiatric tool but as something that may help when the brain inflammation itself is producing catatonic symptoms that immunotherapy alone cannot resolve.

Legal Barriers and Consent Challenges

Here is where the reality gets uncomfortable. Catatonia, by its very nature, often renders people unable to communicate, move, eat, or make decisions. Patients who are mute and immobile cannot give informed consent for their own treatment. And ECT, far more than other medical procedures, is subject to layers of legal restriction that can delay or block life-saving care.

In the United States, involuntary ECT laws vary by state, with some states imposing requirements that go well beyond what is needed for other emergency medical procedures. A review in the Harvard Review of Psychiatry examined the particularly exacting mandates in California, Texas, and New York, concluding that ECT is more heavily regulated than comparable clinical interventions, and that in some cases these regulations interfere with life-saving treatment for malignant catatonia.²² Getting a court order for emergency ECT can take days in states where the process is cumbersome, and days matter when someone with malignant catatonia is deteriorating.

The situation varies internationally. In Norway, the Mental Health Act allows involuntary pharmaceutical treatment and forced nutrition but does not specifically allow involuntary ECT. A retrospective study of Norwegian medical records found that all cases of ECT given without patient consent relied on a general “plea of necessity” in the penal code rather than any specific health-law authorization. The primary reason for overriding consent was that the treatment was considered life-saving.²³ The authors described this as a legal vacuum that undermines patients’ rights and legal security regardless of whether one supports or opposes the treatment itself.

The deeper issue is that stigma around ECT, rooted partly in its history and partly in popular culture depictions, has produced a regulatory environment that treats it as more dangerous or invasive than the evidence supports. The mismatch between ECT’s actual safety profile and its legal treatment creates real harm when a patient with malignant catatonia needs rapid intervention and the clinical team has to navigate a weeks-long court process.

Ketamine as an Emerging Alternative

For patients who cannot undergo ECT, whether due to medical contraindications, lack of access, or legal barriers, ketamine has emerged as an early-stage alternative. Two elderly women with bipolar disorder and catatonia who were deemed not medically fit for ECT were treated with intravenous ketamine. Both responded with complete resolution of their catatonic symptoms and returned to their baseline functioning.²⁴ This gained particular attention during the COVID-19 pandemic, when ECT availability was limited because the procedure generates aerosols during anesthesia.

Case reports have also explored sublingual ketamine and intranasal esketamine (a ketamine-related compound already approved for depression) in patients with chronic catatonia who had not responded to standard treatments.²⁵ The theoretical basis is plausible: catatonia involves disruption of glutamate signaling among other neurotransmitter pathways, and ketamine acts on the glutamate system.²⁶

The evidence base for ketamine in catatonia remains thin, limited to case reports and small series. No one is suggesting it should replace ECT, which has decades of data behind it. But for patients who genuinely cannot access ECT, whether because their body cannot tolerate anesthesia, because the nearest ECT-capable facility is hours away, or because legal obstacles create dangerous delays, ketamine represents a potential bridge or backup. The research community has flagged it as something that merits proper clinical trials, though those trials have yet to materialize.